Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | CES2 | O00748 | 1/20 | 0.49 |
| ▸ | CES1 | P23141 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | BTN3A1 | O00481 | 3/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL851467 | 0.96 | BTN3A1 (0.48) | CA1CA2CES2CES1MAPT | |
| SCHEMBL15457700 | 0.96 | BTN3A1 (0.48) | CA1CA2CES2CES1MAPT | |
| SCHEMBL20059213 | 0.96 | BTN3A1 (0.48) | CA1CA2CES2CES1MAPT | |
| SCHEMBL13051654 | 0.96 | BTN3A1 (0.48) | CA1CA2CES2CES1MAPT | |
| SCHEMBL15588696 | 0.96 | BTN3A1 (0.48) | CA1CA2CES2CES1MAPT | |
| SCHEMBL28842286 | 0.96 | BTN3A1 (0.48) | CA1CA2CES2CES1MAPT | |
| SCHEMBL850882 | 0.96 | BTN3A1 (0.48) | CA1CA2CES2CES1MAPT | |
| SCHEMBL851091 | 0.96 | BTN3A1 (0.48) | CA1CA2CES2CES1MAPT | |
| SCHEMBL30770532 | 0.95 | CA1 (0.45) | CA1CA2CES2CES1MAPT | |
| SCHEMBL30770430 | 0.95 | KMT2A (0.47) | CA1CA2CES2CES1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240366649-A1 | 4-ETHYNYL-3-HYDROXY-TETRAHYDROFURANYL-ADENINE PHOSPHORAMIDATES AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | ROME THERAPEUTICS, INC. | 2024-11-07 | — | — | US | disclosed |
| EP-4358968-A1 | 4-ETHYNYL-3-HYDROXY-TETRAHYDROFURANYL-ADENINE PHOSPHORAMIDATES AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | Rome Therapeutics, Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| WO-2022271878-A1 | 4-ETHYNYL-3-HYDROXY-TETRAHYDROFURANYL-ADENINE PHOSPHORAMIDATES AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | ROME THERAPEUTICS, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| US-20160083413-A1 | 2'-CHLORO NUCLEOSIDE ANALOGS FOR HCV INFECTION | IDENIX PHARMACEUTICALS LLC | 2016-03-24 | — | — | US | disclosed |
| US-20160083413-A1 | 2'-CHLORO NUCLEOSIDE ANALOGS FOR HCV INFECTION | IDENIX PHARMACEUTICALS LLC | 2016-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366649-A1 | 4-ETHYNYL-3-HYDROXY-TETRAHYDROFURANYL-ADENINE PHOSPHORAMIDATES AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | HPRT1, DTYMK, POLI | CA1 4634/4885CA2 4562/4885CES2 2599/4885 |
| US-20160083413-A1 | 2'-CHLORO NUCLEOSIDE ANALOGS FOR HCV INFECTION | SLC28A2, SLC28A1, SLC29A2 | CA1 4616/4885CA2 3286/4885CES2 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.